CHINA First novel coronavirus vaccines begin animal testing

CHINA

First novel coronavirus vaccines begin animal testing

China Daily

18:56, February 23, 2020

The first batch of vaccines against the novel coronavirus has produced antibodies and undergone animal testing, an official of Zhejiang province's Science and Technology Department in East China said at a news conference on Sunday.

微信图片_20200223185427.jpg

Test tube with Coronavirus name label is seen in this illustration taken on Jan 29, 2020. (Photo:Agencies)

Song Zhiheng, deputy director of the department, said the recombinant adenovirus vaccine has begun cultivating recombinant virus and entered animal trials recently.

Virus filtering in Zhejiang province has stepped into the fourth generation, "but we should be aware that since vaccine development takes a long cycle, we must respect scientific rules and conduct careful and safe research," Song said.

Westlake University and the provincial biology laboratory successfully resolved the receptor of coronavirus by applying cryo-electron microscopy, a technique performed on cryogenically cooled samples and embedded in an environment of vitreous water.

The scientific breakthrough also was announced at the news conference.

A laboratory under Westlake University, a private university cultivating high-level talent in advanced technology, disclosed the structure of the ACE2 receptor, the channel for novel coronavirus to enter cells, under cryo-electron microscopy in a paper released on Friday.

The results play an important role in finding and optimizing the inhibitor that stops viruses from entering cells, the university said.

Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue